About Lipocine Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.lipocine.com/
Frequently Asked Questions
What is the 52-week range for LPCN?
The 52-week high is $12.37 and the 52-week low is $1.81.
What is the P/E ratio for LPCN?
The P/E ratio data is currently unavailable.
What is the dividend yield for LPCN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -64.75%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -755.13%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.08.
Analyst Recommendation Trends
Wall Street analyst consensus for LPCN over the last few months:
Latest LPCN News
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HC Wainwright & Co. Reiterates Neutral on Lipocine, Announces $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Neutral and announces $4 price target.
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced the initiation of BLOOM, a Phase 3 study evaluating LPCN 1154 (oral brexanolone) for PPD. First participant dosing is expected in early Q4 2026. LPCN 1154 is being developed as a 48-hour, at-home treatment, targeting the need for rapid symptom relief with a short oral regimen. Lipocine believes this potential profile could address a substantial unmet need in PPD
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Higuchi John W. | +15,970 | $2.23 | $35,613 |
| 2026-09-29 | Higuchi John W. | +9,037 | $2.15 | $19,430 |
| 2026-08-03 | Grissinger Michael | +2,000 | $2.11 | $4,220 |
| 2026-06-03 | Higuchi John W. | +1,764 | $2.19 | $3,863 |
| 2026-06-03 | Jene Jill M. | +1,764 | $2.19 | $3,863 |
| 2026-06-03 | Ono Richard Dana | +1,764 | $2.19 | $3,863 |
| 2026-04-07 | Higuchi John W. | +40,000 | $2.03 | $81,200 |
| 2026-04-06 | Higuchi John W. | +123,000 | $2.05 | $252,150 |
| 2026-04-06 | Patel Mahesh V. | +25,000 | $2.03 | $50,750 |
| 2026-04-02 | Patel Mahesh V. | +25,000 | $2.02 | $50,500 |
| 2026-01-02 | Patel Mahesh V. | +25,000 | $8 | $200,000 |
| 2025-12-18 | Patel Mahesh V. | +8,629 | $4.2 | $36,242 |
| 2025-12-18 | Fogarty Krista | +20,786 | $4.2 | $87,301 |